Octreotide Injection

342 interactions 555 cited references

Also sold as: Bynfezia Bynfezia® Mycapssa Sandostatin Sandostatin® Sandostatin® LAR Depot

About Octreotide Injection

Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treat… Read the full Octreotide Injection drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Levoketoconazole Levomethadyl Mesoridazine Pimozide Ziprasidone

13 Contraindicated 325 Major 4 Moderate

All (342) Contraindicated (13) Major (325) Moderate (4)

Major

Octreotide Injection Pramlintide Symlin An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Primidone Mysoline An increased risk of QT interval prolongation Details Octreotide Injection Probucol An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Procainamide Procan® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Prochlorperazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Promazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Promethazine Phenadoz An increased risk of QT prolongation Details Octreotide Injection Propafenone Rythmol An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Propiomazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Protriptyline An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Quetiapine Seroquel An increased risk of QT interval prolongation Details Octreotide Injection Quinidine Cardioquin® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Quinine An increased risk of QT interval prolongation Details Octreotide Injection Quizartinib Vanflyta An increased risk of QT interval prolongation Details Octreotide Injection Rabeprazole Aciphex Decreased octreotide bioavailability Details Octreotide Injection Ranitidine Decreased octreotide bioavailability Details Octreotide Injection Ranitidine Bismuth Citrate Decreased octreotide bioavailability Details Octreotide Injection Ranolazine Aspruzyo An increased risk of QT interval prolongation Details Octreotide Injection Relugolix Orgovyx Increased risk of QT interval prolongation Details Octreotide Injection Repaglinide Prandin® An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Revumenib Revuforj An increased risk of QT interval prolongation Details Octreotide Injection Ribociclib Kisqali An increased risk of QT interval prolongation Details Octreotide Injection Rilpivirine Edurant An increased risk of QT interval prolongation and torsade de pointes Details Octreotide Injection Risperidone Perseris An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Octreotide Injection Rosiglitazone Avandia® An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Roxatidine Decreased octreotide bioavailability Details Octreotide Injection Ruxolitinib Jakafi Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Saxagliptin Onglyza An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Selpercatinib Retevmo Increased risk of QT interval prolongation Details Octreotide Injection Sematilide An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Sertindole An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Octreotide Injection Sertraline An increased risk of QT interval prolongation Details Octreotide Injection Sevoflurane Petrem Increased risk of QT interval prolongation Details Octreotide Injection Siponimod Mayzent An increased risk of QT interval prolongation Details Octreotide Injection Sirolimus Felycin Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Sitagliptin Brynovin An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Sodium Bicarbonate Alka-Seltzer® Heartburn Decreased octreotide bioavailability Details Octreotide Injection Sodium Phosphate OsmoPrep An increased risk of QT interval prolongation Details Octreotide Injection Sodium Phosphate, Dibasic An increased risk of QT interval prolongation Details Octreotide Injection Sodium Phosphate, Monobasic An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.